Predicting the Incidence and Prognosis of Bone Metastatic Breast Cancer: A SEER-Based Observational Study

Table 3

Median survival of stage IV patients by molecular subtype and bone metastasis.

Characteristics	All		Luminal A		Luminal B		HER2+		TNBC		value
			(HR+/Her2-)		(HR+/Her2+)		(HR-/Her2+)		(HR-/Her2-)
	Median	95% CI	Median	95% CI	Median	95% CI	Median	95% CI	Median	95% CI
Stage IV
No bone metastasis	12	10.883-13.117	14	11.969-16.031	15	10.293-19.707	11	8.419-13.581	9	7.598-10.402	<0.001
Bone metastasis	16	15.126-16.874	19	17.724-20.276	20	16.779-23.221	10	6.887-13.113	9	7.828-10.172	<0.001
Multiple metastases
Brain(+)lung(-)liver(-)	8	5.127-10.873	9	4.942-13.058	13	0-31.739	10	6.080-13.92	6	4.05-7.95	0.028
Brain(-)lung(+)liver(-)	15	13.618-16.382	16	13.924-18.076	23	18.698-27.302	11	7.608-14.392	12	10.219-13.781	<0.001
Brain(-)lung(-)liver(+)	13	11.445-14.555	15	13.035-16.965	11	5.202-16.798	19	13.024-24.976	8	6.108-9.892	<0.001
Brain(+)lung(+)liver(-)	7	4.934-9.066	7	3.337-10.663	10	4.120-15.880	6	1.890-10.110	6	4.458-7.542	0.182
Brain(+)lung(-)liver(+)	7	4.352-9.648	7	4.009-9.991	17	2.391-31.609	7	2.445-11.555	3	0-6.395	0.011
Brain(-)lung(+)liver(+)	8	6.626-9.374	10	7.753-12.247	9	5.132-12.868	5	1.915-8.085	6	3.605-8.395	0.001
Brain(+)lung(+)liver(+)	4	2.876-5.124	4	2.537-5.463	7	4.934-9.066	2	0.674-3.326	4	0.173-7.827	0.591